



**Michael D. Maline**

**Partner**

**CO-CHAIR, CAPITAL MARKETS GROUP**

michael.maline@dlapiper.com

**New York**

T: +1 212 335 4645

F: +1 212 884 8645

Michael serves as co-chair of the firm's Capital Markets practice. He focuses on representing clients in public and private capital markets transactions such as IPOs, follow-on offerings and private placements of equity and debt securities. In addition to his work on offerings by US companies, he has considerable experience in cross-border offerings for foreign issuers selling securities into the United States. His clients include global investment banks, issuers, and investors, and his experience extends to a variety of industries ranging from life sciences, technology and other growth sectors to media and consumer goods.

- Capital Markets
- Corporate

- Life Sciences
- Technology
- Media, Sport and Entertainment

Michael has an extensive background the area of alternative financing techniques, such as confidentially marketed public offerings, bought deals, registered direct offerings, private investments in public equity and at-the-market offerings. Michael also regularly advises clients on corporate and securities compliance and reporting matters.

#### **Initial Public Offerings:**

- Citigroup Global Markets as lead underwriter in Arsanis, Inc.'s US\$46 million initial public offering
- Cowen and Company as lead underwriter in Regado Biosciences, Inc.'s US\$45 million initial public offering
- Cowen and Company as lead underwriter in Nivalis Therapeutics, Inc.'s US\$89 million initial public offering
- JMP Securities as lead underwriter in Summit Therapeutics PLC's (UK) US\$35 million initial public offering
- J.P. Morgan and Stifel as joint global coordinators and joint book-running managers in RenalytixAI plc (UK) US\$85 million initial public offering
- J.P. Morgan as lead underwriter in G1 Therapeutics, Inc.'s US\$105 million initial public offering
- J.P. Morgan as lead underwriter in Intrexon Corporation's US\$160 million initial public offering
- Ladenburg Thalmann as lead underwriter in Immunome, Inc.'s US\$45 million initial public offering

- Ladenburg Thalmann as sole underwriter in Krystal Biotech, Inc.'s US\$30 million initial public offering
- Piper Jaffray & Co. as lead underwriter in Innocoll AG's (Germany) US\$60 million initial public offering
- Piper Jaffray & Co. as lead underwriter in Argos Therapeutics' US\$45 million initial public offering
- SVB Leerink as lead underwriter in Centogene N.V.'s (The Netherlands) US\$64 million initial public offering

#### **Follow-On Offerings:**

- BofA Securities as lead underwriter in BeyondSpring Inc.'s US\$86 million follow-on offering
- BTIG as sole underwriter in two "bought deals" for Cerus Corporation
- Cowen and Company as lead underwriter in Protara Inc.'s US\$150 million concurrent public offering of common and preferred stock
- Credit Suisse as lead underwriter in Centogene N.V.'s (The Netherlands) US\$50 million primary and secondary public offering
- Deutsche Bank Securities Inc. as lead underwriter of Orient-Express Hotels Ltd.'s three public offerings raising aggregate gross proceeds of US\$400 million
- An American multinational investment bank and financial services company as lead underwriter in Sarepta Therapeutics, Inc.'s US\$325 million follow-on offering
- An American multinational investment bank and financial services company as lead underwriter in Krystal Biotech, Inc.'s US\$100 million follow-on offering
- An American multinational investment bank and financial services company as lead underwriter in Sarepta Therapeutics, Inc.'s US\$500 million follow-on offering
- Jefferies as lead underwriter in Solutia Inc.'s US\$160 million follow-on offering
- JMP Securities, as lead underwriter in Flamel Technologies, S.A.'s (France) US\$105 million follow-on offering
- JMP Securities as lead underwriter in Intrexon Corporation's US\$200 million follow-on offering
- J.P. Morgan as lead underwriter in OvaScience, Inc.'s US\$125 million follow-on offering
- J.P. Morgan as lead underwriter in G1 Therapeutics, Inc.'s US\$210 million follow-on offering
- J.P. Morgan as lead underwriter in NPS Pharmaceuticals, Inc.'s US\$87 million follow-on offering
- Morgan Stanley as lead underwriter in a US\$162 million public offering by existing shareholders of Horizon Pharma, Inc.
- Morgan Stanley as lead underwriter in Innocoll AG's (Germany) US\$40 million follow-on offering
- Piper Jaffray & Co. as lead underwriter in Itamar Medical Ltd.'s (Israel) US\$40 million public offering
- Piper Jaffray & Co. as sole underwriter in Global Eagle Entertainment Inc.'s US\$190 million follow-on offering
- William Blair & Company as lead underwriter in Viking Therapeutics, Inc.'s US\$175 million follow-on offering

#### **Alternative Transactions:**

- Cowen and Company, as lead placement agent in Invitae Corporation's US\$275 million PIPE to finance its acquisition of Archer DX
- Cowen and Company, as lead placement agent in Horizon Pharma Inc.'s US\$150 million five percent convertible note offering
- Deutsche Bank Securities as placement agent in a US\$600 million registered direct offering for The St. Joe Company
- Deutsche Bank Securities Inc. as lead placement agent in Smith & Wesson Holding Corporation's two registered direct offerings
- Jefferies as lead placement agent in TFF Pharmaceuticals, Inc.'s US\$26 million PIPE
- Piper Sandler & Co. as sole placement agent in U.S. Well Services, Inc.'s US\$21 million PIPE

## **CREDENTIALS**

---

### **Admissions**

- New York

### **Recognitions**

- Recognized by *The Legal 500 US* for his work on capital markets equity offerings
- Featured multiple times as a New York "Super Lawyer" by *Thomson Reuters*

## Education

- The Johns Hopkins University 1988
- J.D., Tulane University 1994